MUTATEDRASp21 AS A TARGET FOR CANCER THERAPY IN MOUSE TRANSITIONAL CELL CARCINOMA
- 1 October 1999
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 162 (4) , 1519-1526
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- Screening of H‐ras Gene Point Mutations in 50 Cases of Bladder CarcinomaInternational Journal of Urology, 1997
- Peptide‐specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K‐ras p21European Journal of Immunology, 1995
- Identification of H-ras Mutations in Urine Sediments Complements Cytology in the Detection of Bladder TumorsJNCI: Journal of the National Cancer Institute, 1995
- Frequency of H‐ ras mutations in human bladder cancer detected by direct sequencingBritish Journal of Urology, 1994
- Screening of human bladder tumors and urine sediments for the presence of H‐ras mutationsInternational Journal of Cancer, 1993
- Overlapping epitopes encompassing a point mutation (12 Gly → Arg) in p21 ras can be recognized by HLA‐DR, ‐DP and ‐DQ restricted T cellsEuropean Journal of Immunology, 1993
- The Molecular Cell Biology of Interferon-gamma and its ReceptorAnnual Review of Immunology, 1993
- Peptides Presented to the Immune System by the Murine Class II Major Histocompatibility Complex Molecule I-A dScience, 1992
- T-cell responses against products of oncogenes: Generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptidesHuman Immunology, 1992
- Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF.Journal of Experimental Medicine, 1992